These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 23814490)

  • 1. Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma.
    Weirauch U; Beckmann N; Thomas M; Grünweller A; Huber K; Bracher F; Hartmann RK; Aigner A
    Neoplasia; 2013 Jul; 15(7):783-94. PubMed ID: 23814490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
    Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
    Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma.
    Ibrahim AF; Weirauch U; Thomas M; Grünweller A; Hartmann RK; Aigner A
    Cancer Res; 2011 Aug; 71(15):5214-24. PubMed ID: 21690566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
    Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
    Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumour effects of PIM kinase inhibition on progression and chemoresistance of hepatocellular carcinoma.
    Leung MS; Chan KK; Dai WJ; Wong CY; Au KY; Wong PY; Wong CC; Lee TK; Ng IO; Kao WJ; Lo RC
    J Pathol; 2020 Sep; 252(1):65-76. PubMed ID: 32558942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
    Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
    Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Midazolam inhibits proliferation and accelerates apoptosis of hepatocellular carcinoma cells by elevating microRNA-124-3p and suppressing PIM-1.
    Qi Y; Yao X; Du X
    IUBMB Life; 2020 Mar; 72(3):452-464. PubMed ID: 31651086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents.
    Casillas AL; Toth RK; Sainz AG; Singh N; Desai AA; Kraft AS; Warfel NA
    Clin Cancer Res; 2018 Jan; 24(1):169-180. PubMed ID: 29084916
    [No Abstract]   [Full Text] [Related]  

  • 9. PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis.
    Lim JT; Singh N; Leuvano LA; Calvert VS; Petricoin EF; Teachey DT; Lock RB; Padi M; Kraft AS; Padi SKR
    Mol Cancer Ther; 2020 Sep; 19(9):1809-1821. PubMed ID: 32753387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis.
    Zhang L; Wang H; Li W; Zhong J; Yu R; Huang X; Wang H; Tan Z; Wang J; Zhang Y
    Oncotarget; 2017 Jan; 8(2):3289-3303. PubMed ID: 27924057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
    Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
    Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer.
    Zhang Y; Talmon G; Wang J
    Cell Death Dis; 2015 Aug; 6(8):e1845. PubMed ID: 26247730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
    Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
    PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.
    Foulks JM; Carpenter KJ; Luo B; Xu Y; Senina A; Nix R; Chan A; Clifford A; Wilkes M; Vollmer D; Brenning B; Merx S; Lai S; McCullar MV; Ho KK; Albertson DJ; Call LT; Bearss JJ; Tripp S; Liu T; Stephens BJ; Mollard A; Warner SL; Bearss DJ; Kanner SB
    Neoplasia; 2014 May; 16(5):403-12. PubMed ID: 24953177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockdown of PRDX2 sensitizes colon cancer cells to 5-FU by suppressing the PI3K/AKT signaling pathway.
    Xu J; Zhang S; Wang R; Wu X; Zeng L; Fu Z
    Biosci Rep; 2017 Jun; 37(3):. PubMed ID: 28432271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of stemonamide synthetic intermediates as a novel potent anticancer drug with an apoptosis-inducing ability.
    Li YY; Wang YY; Taniguchi T; Kawakami T; Baba T; Ishibashi H; Mukaida N
    Int J Cancer; 2010 Jul; 127(2):474-84. PubMed ID: 19921695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth.
    Singh N; Padi SKR; Bearss JJ; Pandey R; Okumura K; Beltran H; Song JH; Kraft AS; Olive V
    Mol Oncol; 2020 May; 14(5):974-990. PubMed ID: 32146726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells.
    Tian Z; Zhao JJ; Tai YT; Amin SB; Hu Y; Berger AJ; Richardson P; Chauhan D; Anderson KC
    Blood; 2012 Nov; 120(19):3958-67. PubMed ID: 22983447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
    Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
    Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.
    Warfel NA; Sainz AG; Song JH; Kraft AS
    Mol Cancer Ther; 2016 Jul; 15(7):1637-47. PubMed ID: 27196781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.